Q-omics provides the consensus-scored RPS15AP24 profile across patient tissues and cancer cell-line models. RPS15AP24 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RPS15AP24 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, RPS15AP24 RNA expression shows 16,118 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUSC, KIRC, and ACC as cancer lineages where RPS15AP24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15AP24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15AP24 survival associations across molecular data types. RPS15AP24 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15AP24 RNA expression–survival associations across cancer types. High RPS15AP24 expression shows unfavorable associations in ACC and READ, but favorable associations in LUSC, CESC, THCA and MESO. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for RPS15AP24 RNA expression.
This table summarizes RPS15AP24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS15AP24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15AP24 shows higher tumor expression in KIRC, COAD, CHOL, LIHC, READ and PRAD. The KIRC box plot shows higher RPS15AP24 RNA expression in tumor versus normal tissue (log2 FC = +0.750, t-test p < 0.001).
This table shows molecular features associated with RPS15AP24 in patient tissues and cancer cell lines. In patient samples, RPS15AP24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
